The clinical benefit of intravenous (IV) alteplase in acute ischemic stroke is time dependent. We assessed the overall temporal changes in door-to-needle (DTN) time and examine the factors associated with DTN time ≤60 and ≤45 minutes.
ach year, nearly 800 000 people in the United States experience a new or recurrent stroke, of which nearly 90% are ischemic strokes.
1 Intravenous (IV) tissue plasminogen activator therapy (IV alteplase) is the only Food and Drug Administration approved medication for acute ischemic stroke (AIS) thrombolysis, and national guidelines recommend an arrival to treatment initiation (door-to-needle [DTN]) time of ≤60 minutes. 2 In 2013, the National Quality Forum endorsed this as a performance metric. Among clinically eligible patients, IV alteplase is recommended within 4.5 hours of the time the patient was last known to be well. 3 In 2010, the American Heart Association/American Stroke Association launched its Target Stroke initiative with a phase I goal of ≤60 minutes for the DTN time for at least 50% of AIS patients treated with IV alteplase. Subsequently in 2014, Target Stroke phase II goals were established: to achieve a DTN time within 60 minutes in at least 75% of patients, and DTN time within 45 minutes in at least 50% of patients. 4, 5 These initiatives have demonstrated the ability to improve the timeliness of IV alteplase administration in US hospitals.
Since 2001, the Centers for Disease Control and Prevention (CDC) has funded the development and implementation of the Paul Coverdell National Acute Stroke Program (PCNASP), an acute stroke quality of care registry, which is state-centric and hospital based. In 2004, PCNASP was implemented in 4 state health departments (Georgia, Illinois, Massachusetts, and North Carolina), in 2007 funding to 6 health departments (Georgia, Massachusetts, Michigan, Minnesota, North Carolina, and Ohio), in 2012 funding extended to 11 states (Arkansas, California, Georgia, Iowa, Massachusetts, Michigan, Minnesota, New York, North Carolina, Ohio, and Wisconsin), and in 2015 funding to 9 states (California, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio, Washington, and Wisconsin). This public health program not only provides surveillance on stroke care quality, but implements targeted interventions to improve prehospital and in-hospital quality of acute stroke care, and improve transitions from hospital to home. Funded state health department staff provide regular and ongoing technical assistance to participating hospitals and convene hospitals as a group to promote cross-pollination of successful strategies to improve stroke quality of care on a variety of established stroke care performance measures, including improving DTN times. 6 In this study, we conducted analyses to assess improvements in DTN times among AIS patients treated with IV alteplase in the CDC PCNASP between January 2008 and December 2017, and explored potential patient and hospital factors associated with achieving the time targets of 60 minutes or less and 45 minutes or less.
METHODS
Data collected by PCNASP is not currently publically available to other researchers for purposes of reproducing the results or replicating the procedure. However, PCNASP has established protocols where researchers can submit project proposals in which CDC analysts will provide generated result tables to fulfill research or analytic requests.
PCNASP includes patients aged ≥18 years with a physician's clinical diagnosis in the medical record of AIS, intracerebral hemorrhage (ICH), subarachnoid hemorrhage, or transient ischemic attack (TIA). The details of the PCNASP program design have been published previously. 7 This analysis included all cases collected in the PCNASP from January 2008 to December 2017, with a clinically assigned diagnosis of AIS and treated with IV alteplase within 4.5 hours of the time last known to be well. Because we used the clinical diagnosis for case identification, International Classification of Diseases, Ninth Revision, Clinical Modification codes were not used in this analysis.
During 2008 to 2017, there were 496 336 patients from 573 participating hospitals with a clinical diagnosis of AIS in the PCNASP. Among them, 57 712 (12%) received IV alteplase, but 16 629 (3%) of patients without DTN times were excluded because they received IV alteplase at outside hospitals and were subsequently transferred to stroke centers. Among the remaining 41 083 (8%) receiving IV 
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Of the 419 participating hospitals, 12% had <100 beds, 18% had 100-199 beds, 37% had 200-399 beds, and 33% had 400+ beds ( Figure 3 ). Sixteen percent of the hospitals had annual stroke admissions <100, 41% had 100-299, and 43% had 300+. Forty-seven percent of hospitals had a stroke unit, 52% were teaching hospitals, and 59% were certified stroke centers ( Figure 3 ). Among hospitals with >200 beds, 90% were teaching hospitals and 80% were stroke certified center versus only 49% and 59% among hospitals with <200 beds, respectively (Data not shown).
The median age of patients receiving IV alteplase within 4.5 hours of time last known to be well was 71 years (interquartile range, 59-82) and 41.4% of patients were 75 years or older (Table 1) . Overall, 50.3% of patients were men and 74.7% were white. Seventy-seven percent of patients arrived by EMS and the median NIHSS score was 8 (interquartile range, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . The majority of patients (70.6%) had hypertension, 43.5% had dyslipidemia, 25.6% had diabetes mellitus, 19.9% had AF, and 17.6% had a prior stroke (Table 1) .
Door-to-Needle Time Within 60 Minutes
Overall, 21 217 (53.4%) patients received IV alteplase within 60 minutes and there was a significant increase in the proportion of patients treated within 60 minutes from 2008 to 2017 (26.4% in 2008 to 66.2% in 2017, P<0.001, Figure 1 ). Unadjusted analyses showed statistically significant differences in the proportion of patients treated within 60 minutes by age group, sex, race, arrival by EMS, NIHSS recorded, NIHSS score, and medical history of prior stroke, hypertension, myocardial infarction/coronary artery disease, heart failure, diabetes mellitus, and AF (Table 1) . Dyslipidemia and being a smoker were not associated with IV alteplase within 60 minutes (P=0.08 and P=0.94, respectively). Hospital characteristics varied by DTN time. Hospitals who reported annual stroke admissions ≥300, having a stroke unit, being a teaching hospital, or being a certified stroke center were associated with a DTN time ≤60 minutes (P<0.001 for all).
Patients receiving IV alteplase within 60 minutes were more likely to be discharged to home, and less likely to develop symptomatic ICH within 36 hours after IV alteplase as compared with those treated beyond 60 minutes. The percent of patients who died in-hospital was lower among those who were treated within 60 minutes than those treated beyond 60 minutes, but this was not statistically significant (6.0% versus 6.4%, P=0.06; Table 1 ). GEE multivariate model results showed those aged 55 to 84 years were more likely to be treated within 60 minutes. The AOR for patients aged 55 to 64 years was 1.16 (95% CI, 1.07-1.25), 1.16 (95% CI, 1.08-1.25) for ages 65-74 years, and 1.15 (95% CI, 1.07-1.25) for ages 75 to 84 years compared with those aged 18 to 54 years old. Women and blacks were less likely to be treated within 60 minutes as compared with their counterparts (AOR of 0.83, 95% CI, 0.79-0.87; and 0.86, 95% CI, 0.81-0.92, respectively). Patient arrival by EMS and those with a higher NIHSS score were more likely to receive IV alteplase within 60 minutes. As compared with mild stroke (NIHSS score of 0-4), the AOR was 1.55 (95% CI, 1.46-1.65) for NIHSS scores of 5 to 9, 1.90 (95% CI, 1.76-2.04) for NIHSS scores of 10 to 14, 1.94 (95% CI, 1.80-2.10) for NIHSS scores of 15 to 20, and 1.69 (95% CI, 1.55-1.83) for NIHSS scores >20, respectively (P<0.001 for all). Importantly, a medical history of stroke, hypertension, myocardial infarction/coronary artery disease, heart failure, diabetes mellitus, or AF were inversely associated with DTN time ≤60 minutes. Hospital characteristics associated with greater odds of DTN time ≤60 minutes were bed size of ≥200, annual stroke admissions ≥300, or having a stroke unit. After controlling for demographic and clinical characteristics, (Table 1) . In GEE adjusted analyses, patients aged 55 to 74 years old were more likely to receive IV alteplase in <45 minutes compared with those aged 18 to 54 years old (Table 2) . Women, blacks, patients with a medical history of stroke, hypertension, heart failure, diabetes mellitus, or AF were less likely to be treated within 45 minutes. Patients arriving by EMS, patients with higher NIHSS scores, from hospitals with ≥400 beds, or ≥300 annual stroke admissions, or from hospitals having a stroke unit were more likely to be treated within 45 minutes. After adjusting for demographic and clinical characteristics, significant improvements in achieving DTN time ≤45 minutes were identified between 2009 and 2017 compared with 2008 except for in 2010 (Table 2) .
Clinical Outcomes Associated With DTN
Overall, the in-hospital all-cause mortality among those receiving IV alteplase within 4.5 hours of time last known to be well was 6.2%, and it significantly decreased from 7.2% in 2008 to 5.1% in 2017 (P<0.001, Figure 4 ). There were 1 471 (3.7%) patients who experienced symptomatic ICH within 36 hours, and 276 (0.7%) had life threatening or serious systemic hemorrhage within 36 hours ( Table 1 ). The percentage of symptomatic ICH within 36 hours decreased significantly from 6.3% in 2008 to 3.4% in 2017 (P<0.001). Overall 44% patients were discharged to home, significantly increased from 23.6% in 2008 to 50.9% in 2017, respectively (P<0.001).
GEE adjusted analyses showed both DTN time ≤60 and DTN time ≤45 were significantly associated with the lower in-hospital all-cause mortality, symptomatic ICH within 36 hours, and higher odds of discharge to home compared with longer DTN time (Table 3) .
DISCUSSION
Our results showed a substantial increase in achieving DTN time ≤60 minutes and DTN time ≤45 minutes over a decade in PCNASP. By 2013, PCNASP reached the goal of at least 50% of patients receiving IV alteplase within 60 minutes of hospital arrival. Revised goals for DTN time targets are now ≤60 minutes for at least 75% of patients and DTN time ≤45 minutes for at least 50% of patients. Based on the most recent trends demonstrated in this analysis, if current trends continue, there is potential to achieve these goals in the PCNASP in 2020. About the safety of decreasing DTN times, we observed that these reductions in DTN time were associated with decreases in adverse events from thrombolysis or in-hospital all-cause mortality, and were associated with an increase in discharges to home.
Consistent with results from other studies, 8, 9 we found that arrival by EMS, increasing age (except 85+), and greater stroke severity as measured by NIHSS were associated with shorter DTN times. Patients aged 55 to 74 years were more likely to meet both DTN time targets as compared with those aged 18 to 54 years. Women, blacks, and patients with stroke risk factors and other cardiovascular diseases were less likely to receive IV alteplase within DTN goals. A meta-analysis of 18 studies found that women were consistently less likely to receive IV alteplase, and another study showed blacks were significantly less likely to receive IV alteplase. 10, 11 Previous studies only identified that a medical history of AF, diabetes mellitus, and prior stroke were associated with not meeting the DTN time ≤60 minutes time target. 8 In our study, in addition to the factors reported by others, we found patients with medical history of hypertension, or heart failure were also less likely to receive IV alteplase within DTN target goals, which might indicate clinically significant challenges in the care of patients with comorbidities. Our finding that achievement of the time targets were less likely among those aged 18 to 54 years could indicate challenges in diagnosing a stroke versus a stroke mimic in younger patients.
Although the best practices have been developed, recent time target initiatives have necessitated implementation of numerous strategies within hospitals and among EMS providers to achieve DTN goals. 4, 5, 12 The study from the Get With The Guidelines-Stroke initiative showed significant improvement in DTN ≤60 minutes after the postintervention (initiative). 13 In PCNASP, we observed similar trends in improvements but with a more steady increase. This might reflect the ongoing efforts of quality improvement from the state health department making improvement before the Get With The Guidelines Target Stroke initiative. In a recent narrative review of DTN quality improvement strategies among single centers and across multiple hospitals, successful activities in reducing DTN time included prenotification of arrival by EMS and single-call activation of the stroke team. 14 We found that the rates of achieving DTN time targets were different among the participating PCNASP hospitals, likely reflecting varying levels of infrastructure and resources required for acute stroke care, but also reflecting variances in patients' comorbidities, stroke severity, and age. In the SITS-ISTR study (Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Registry), adjusted analyses showed that stroke centers with stroke case volumes ≥100 per year had greater annual decreases in DTN time. 15 One study used the failure mode, effects and criticality analysis approach to identify the common critical failures in an academic hospital and a community hospital in Another study from 10 European stroke centers found delays in DNT times for those arriving within 30 minutes of symptom onset, but DTN time was shorter among those arriving near the end of treatment windows, among men, and, similar to our findings those over age 50 versus younger, and among those <80 years versus over 80 years. 17 Our study has several limitations. PCNASP is a quality improvement program, focused on improving care across the continuum, including in-hospital and prehospital care, as well as the posthospital transition from hospital to home; therefore, the results may not be generalizable. The hospitals that participated in the PCNASP, as well as the program requirements for participation changed over time. However, we controlled for hospital characteristics through the GEE models to minimize this bias. The PCNASP does not collect information on glucose level at the time of admission, CT scan results, or whether antihypertensive medications were required in the ED before giving IV alteplase, which might affect treatment decisions. Finally, about the concern for case selection bias with registry data, CDC requires that funded states track the extent of case abstraction of participating hospitals within the state registries; however, we do not conduct a formal national audit of the data using a sole source abstractor. While the potential for case selection bias exists, the majority of hospitals are making every effort to abstract all stroke cases. As noted above, we are unable to account for selection bias in the decision to treat with IV alteplase, but we can provide information on the real-world experience in the use of IV alteplase and DTN time targets. The strength of this study is that it included a large cohort of patients treated in a variety of academic and nonacademic hospitals with greatly varying stroke case volumes. *Variables included in multivariable models were age, sex, race, arrival by EMS, NIHSS score, smoking status, history of hypertension, dyslipidemia, myocardial infarction or coronary artery disease, heart failure, diabetes mellitus, nonvalvular atrial fibrillation, stroke, hospital size, annual stroke admissions, stroke unit, and year of admission. ICH indicates intracerebral hemorrhage; IV, intravenous; and PCNASP, Paul Coverdell National Acute Stroke Program.
In conclusion, significant improvements in DTN time were observed in PCNASP over a decade, with steady increases that began in 2010. We found that patients aged 55 to 74 years, arrival by EMS, and patients with more severe stroke were more likely to receive IV alteplase within either DTN targets. Women, blacks, and patients with stroke risk factors or other cardiovascular disease were less likely to be treated according to DTN goals. Focusing on shortening DTN times through dedicated quality improvement activities has been successful, and has not been associated with an increase in serious adverse events related to thrombolysis. However, opportunities exist to reduce the disparities in treatment, especially among women and blacks, and further improve acute stroke care and systems of care.
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